Revenue Growth
MCK achieved an 11.4% increase in revenue, driven by strong demand across its product lines.
Source: 10-Q Income Statement
Computed from published fixed rules, not a model's judgement — though one input, the count of high-severity risks, comes from the AI analysis below.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
MCK reported strong financial performance in Q3 FY2026, with significant increases in revenue, operating income, and net income, despite ongoing cost pressures.
Revenue
$106.16B
+11.40% YoY
EPS (Diluted)
$9.59
+37.99% YoY
Gross Margin
3.5%
+0.0 pts YoY
Operating Income
$1.62B
+32.27% YoY
Source: SEC XBRL
Mckesson (MCK) reported Q3 FY2026 revenue of $106.16B, up 11.4% year over year. Operating margin was 1.5%, up 0.2 points from 1.3% a year earlier. MCK's fiscal Q3 FY2026 corresponds to calendar Q4 2025.
Last 4 quarters: 4 beats
| Quarter | Actual EPS (USD) | Consensus (USD) | Result |
|---|---|---|---|
| Jun 2026 | 9.93 | 9.63 | Beat +3.1% |
| Mar 2026 | 11.69 | 11.68 | Beat +0.1% |
| Dec 2025This filing | 9.34 | 9.31 | Beat +0.3% |
| Sep 2025 | 9.86 | 9.13 | Beat +8.0% |
Adjusted (non-GAAP) EPS of $9.34 versus the $9.31 analyst consensus — a +0.3% beat for Dec 2025. Analyst consensus is quoted on the adjusted (non-GAAP) basis the street uses. GAAP diluted EPS for this quarter was $9.59.
Compiled by AI from this SEC filing
MCK achieved an 11.4% increase in revenue, driven by strong demand across its product lines.
Source: 10-Q Income Statement
Operating income rose by 32.3%, reflecting improved operational efficiencies and cost management.
Source: 10-Q Income Statement
Operating cash flow turned positive at $2.73B, indicating enhanced cash generation capabilities.
Source: 10-Q Cash Flow
Compiled by AI from this SEC filing · 2 high, 1 medium, 0 low
MCK's long-term debt increased by 17.4% to $6.56B, which could pressure future cash flows if interest rates rise.
Source: 10-Q Balance Sheet
The company continues to have negative stockholders' equity, though it improved by 57.9% YoY, which may affect its financial flexibility.
Source: 10-Q Balance Sheet
With a current ratio of 0.88, MCK may face liquidity challenges in meeting short-term obligations.
Source: 10-Q Key Ratios
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue $B | 106.16 $B | 95.29 $B | +11.40% |
Cost of Revenue $B | 102.47 $B | 92.01 $B | +11.37% |
Gross Profit $B | 3.69 $B | 3.28 $B | +12.21% |
Operating Income $B | 1.62 $B | 1.22 $B | +32.27% |
Net Income $B | 1.19 $B | 0.88 $B | +34.93% |
EPS (Basic) $ | 9.63 $ | 6.98 $ | +37.97% |
EPS (Diluted) $ | 9.59 $ | 6.95 $ | +37.99% |
SG&A Expense $B | 2.03 $B | 2.03 $B | +0.10% |
Answers draw on this SEC filing and the data on this page
McKesson's Q1 FY2027 revenue grew 8% due to pharmaceutical and specialty sales, but earnings per share fell 18% as a $293 million noncontrolling interest charge from the Medical-Surgical Solutions separation overshadowed operating gains.
McKesson (MCK) delivered a strong fiscal year 2026, with revenue surging 12.4% to $403.4B and net income jumping 44.5% to $4.76B, driven by operating leverage and aggressive share buybacks that boosted EPS by 49.1% to $38.55.
Other companies in Health Care Distributors